文献速递类风湿关节炎脊柱关节炎其他结缔组织病

英夫利西单抗围手术期时机与择期髋膝关节置换术后严重感染风险

Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2017-11-02

该回顾性队列研究纳入2007至2013年美国Medicare中接受择期髋或膝关节置换且6个月内使用英夫利西单抗的类风湿关节炎、炎症性肠病、银屑病、银屑病关节炎或强直性脊柱炎患者。倾向性校正分析显示,英夫利西单抗停药时机<4周与8-12周相比,30天内住院感染和1年内假体关节感染风险均未增加;糖皮质激素剂量>10 mg/天与感染风险增加相关。

要点

  • 英夫利西单抗停药<4周与8-12周相比,30天住院感染风险无增加(OR 0.90,95%CI 0.60-1.34)。
  • 英夫利西单抗停药<4周与8-12周相比,1年假体关节感染风险无增加(HR 0.98,95%CI 0.52-1.87)。
  • 糖皮质激素>10 mg/天与30天感染(OR 2.11,95%CI 1.30-3.40)和假体关节感染(HR 2.70,95%CI 1.30-5.60)风险增加相关。

核心结论

  • 择期髋或膝关节置换前4周内给予英夫利西单抗与较长时间停用相比,未增加短期或长期严重感染风险。
  • 糖皮质激素使用,尤其是剂量>10 mg/天,与感染风险增加相关。

研究设计与样本

  • 回顾性队列研究,评估2007至2013年美国Medicare中类风湿关节炎、炎症性肠病、银屑病、银屑病关节炎或强直性脊柱炎患者。
  • 纳入6个月内接受英夫利西单抗且行择期膝或髋关节置换的患者,共4288例手术。
  • 采用倾向性校正分析,评估英夫利西单抗停药时机与30天内住院感染或1年内假体关节感染的关系。

主要发现

  • 4288例手术中,270例(6.3%)在30天内发生住院感染。
  • 英夫利西单抗停药时机<4周与8-12周相比,30天感染倾向性校正OR为0.90(95%CI 0.60-1.34)。
  • 假体关节感染率为2.9/100人年,停药时机<4周与8-12周相比HR为0.98(95%CI 0.52-1.87)。
  • 糖皮质激素剂量>10 mg/天与30天感染风险增加相关(OR 2.11,95%CI 1.30-3.40)。
  • 糖皮质激素剂量>10 mg/天与假体关节感染风险增加相关(HR 2.70,95%CI 1.30-5.60)。

临床怎么用

  • 择期髋或膝关节置换前4周内使用英夫利西单抗未显示增加严重感染风险,支持不必为手术而延长停用时间。
  • 围手术期应关注糖皮质激素剂量,尤其>10 mg/天时感染风险增加。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The optimal timing of tumor necrosis factor antagonists before elective surgery is unknown. This study evaluated the association between infliximab timing and serious infection after elective hip or knee arthroplasty. METHODS: A retrospective cohort study evaluated US Medicare patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or ankylosing spondylitis who received infliximab within 6 months of elective knee or hip arthroplasty from 2007 to 2013. Propensity-adjusted analyses examined whether infliximab stop timing (time between the most recent infusion and surgery) was associated with hospitalized infection within 30 days or prosthetic joint infection (PJI) within 1 year. RESULTS: Hospitalized infection within 30 days occurred after 270 of 4,288 surgeries (6.3%). Infliximab stop timing <4 weeks versus 8-12 weeks was not associated with an increase in infection within 30 days (propensity-adjusted odds ratio [OR] 0.90 [95% confidence interval (95% CI) 0.60-1.34]). The rate of PJI was 2.9 per 100 person-years and was not increased in patients with stop timing <4 weeks versus 8-12 weeks (hazard ratio [HR] 0.98 [95% CI 0.52-1.87]). Glucocorticoid dosage >10 mg/day was associated with increased risk of 30-day infection (OR 2.11 [95% CI 1.30-3.40]) and PJI (HR 2.70 [95% CI 1.30-5.60]). Other risk factors for infection included elderly age, comorbidities, revision surgery, and previous hospitalized infection. CONCLUSION: Administering infliximab within 4 weeks of elective knee or hip arthroplasty was not associated with a higher risk of short- or long-term serious infection compared to withholding infliximab for longer time periods. Glucocorticoid use, especially >10 mg/day, was associated with an increased infection risk.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. George MD, Baker JF, Hsu JY, et al. Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty. Arthritis Care Res (Hoboken). 2017. PMID: 28129484. doi:10.1002/acr.23209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。